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Summary 
CD14 is a 55-kD  protein found both as a glycosylphosphatidyl inositol-linked protein on the 
surface  of mononudear phagocytes and as a soluble  protein in the blood. CD14 on the call membrane 
(mCD14) has been shown to serve as a receptor for complexes of lipopolysaccharide (LPS) with 
LPS binding protein,  but a function for soluble CD14 (sCD14) has not been described. Here 
we show that sCD14 enables responses to LPS by cells that do not express CD14. We have examined 
induction of endothdial-leukocyte adhesion molecule 1 expression by human umbilical vein 
endothdial cells, interleukin 6 secretion by U373 astrocytoma cells, and cytotoxicity of bovine 
endothelial ceUs. None of these cell types express mCD14, yet all respond to LPS in a serum- 
dependent  fashion,  and  all  responses  are  completely blocked  by  anti-CD14  antibodies. 
Immunodepletion of sCD14 from serum prevents responses to LPS, and the responses are restored 
by addition of sCD14. These studies suggest that a surface anchor is not needed for the function 
of CD14 and further imply that sCD14 must bind to additional  proteins  on the cell surface 
to associate with the cell and transduce  a signal. They also indicate that sCD14 may have an 
important role in potentiating responses to LPS in cells lacking mCD14. 
1~ 
cent studies have described proteins that enable mono- 
cytes and PMN to respond to nanogram per milliliter 
concentrations of Gram-negative bacterial LPS (endotoxin) 
(1, 2). LPS is first recognized by soluble serum proteins, ei- 
ther LPS binding protein (LBP)  1 (2) or the abundant factor 
in serum, termed septin (3). The resulting complex is then 
bound by CD14 (1), a glycosylphosphatidyl inositol (GPI)- 
anchored protein on the surface of phagocytic cells (4, 5). 
Blockade of cell surface CD14 with mAbs prevents binding 
of LPS/LBP  complexes (1), prevents synthesis of TNF by 
monocytes (1), and prevents activation of adhesion receptors 
on PMN (6) that occur in response to low levels of LPS. These 
findings thus suggest a pivotal role for cell membrane (m)CD14 
and serum proteins  in responses to LPS. 
The generality of the above scheme has appeared limited 
since several cell types respond to LPS but do not express 
1 Abbreviations used in thispaper: CPAE, cultured bovine pulmonary arterial 
endothelial; ELAM-1, endothelial-lenkocyte adhesion  molecule 1; GPl, 
glycosylphosphatidyl  inositol; HUVEC, human umbilical vein endothelial 
cells; LBP, LPS binding protein; mCD14, cell membrane CD14; NHS, 
normal human serum;  sCD14,  soluble CD14. 
CD14. For example, human umbilical vein endothelial cells 
(HUVEC)  respond  to  LPS  with  increased expression  of 
tissue factor (7), endothelial-leukocyte adhesion mohcule 1 
(ELAM-1) (8), and Ib6 (9, 10). The astrocytoma line U373 
responds to LPS with strong synthesis of Ib6 (10a), and we 
have recently observed that bovine brain microcapillary en- 
dothdial cells and cultured bovine  pulmonary arterial en- 
dothelial  (CPAE) calls respond to LPS with enhanced per- 
meability and cell death (11). CD14 has not been reported 
on the surface of U373 cells or endothdial cells, and sensitive 
binding studies with fluorescent or radiolabded anti-CD14 
antibodies have failed to detect any CD14 on HUVEC (12; 
S. K. Lo and S. D. Wright, unpublished observations). Here 
we report that CD14 is essential for the response of each of 
these cell types to LPS, but that the CD14 is derived from 
the soluble pool of CD14 present in serum,  not from the 
surface of the responding ceU. 
Materials and Methods 
Reagents.  LPS from Haemophilus influenzae (Hib) (strain 10211) 
was isolated by magnesium ethanol precipitation (11, 13). Anti- 
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from ascites fluid by chromatography on protein G. mAb 60b was 
coupled to CNBr-Sepharose to yield 1 mg IgG/ml of packed gel. 
3C10 was biotinylated using N-hydroxysuccinimide biotin.  My4 
(anti-CD14) and anti-CD18 antibodies were purchased from Coulter 
Immunology (Hialeah, FL) and Dakopatts  (Copenhagen,  Den- 
mark), respectively.  The anti-CD14 mAb AML2-23 was purchased 
from Medarex  (Lebanon,  NH), and alkaline  phosphatase-conjugated 
streptavidin was purchased from Vector Labs (Burlingame, CA). 
LBP was purified from human  ascites fluid as described (3). 
Depletion of  Soluble(s)CDl 4 from Serum.  A 1-ml column ofanti- 
CD14-Sepharose was equilibrated  in PBS and 2 ml of  normal human 
serum (NHS) was passed over at a flow rate of  0.05 ml/min. Deple- 
tion of sCD14 from serum was measured using a capture ELISA. 
Briefly,  ELISA  Terasaki  plates were coated with AML2-23, and then 
blocked with FCS. Dilutions of  human serum were incubated with 
the plates for 60 min at 21~  then with biotinylated 3C10 for 
60 min at 21~  Retention of biotin was measured by adding alka- 
line phosphatase-conjugated streptavidin in a final step. Retained 
alkaline phosphatase activity was measured with a fluorescence  plate 
reader (Cytofluor 2300; MiUipore, Bedford, MA) using the fluoro- 
genic substrate, attophos (JBL Scientific, San Luis Obispo, CA). 
This assay showed that serum passed over an anti-CD14 column 
contained <0.1% of the sCD14 present in untreated serum. Removal 
of sCD14 caused no change in the ability of the serum to mediate 
adhesion of  LPS-coated erythrocytes to macrophages or to mediate 
stimulation  of adhesivity of PMN by LPS. Septin was thus not 
depleted by this procedure. To confirm that anti-CD14 did not con- 
taminate the CD14-depleted serum, a sensitive ELISA for murine 
anti-CD14 antibody was performed. ELISA wells were coated with 
1/zg/ml sCD14, blocked  with nonfat dry milk (1%), then incubated 
with dilutions of anti-CD14 or serum for 45 min. Retained mouse 
IgG  was  detected  with  an  alkaline phosphatase-conjugated 
anti-mouse IgG and the fluorogenic substrate, attophos. No anti- 
CD14 could be detected in the serum passed over the 60b column 
(data not shown). The sensitivity of the assay assures that the final 
concentration of anti-CD14 was <0.002 #g/ml in assays that used 
the CD14-depleted serum. 
sCDI4,  sCD14  was obtained from two different sources. Serum 
sCD14 was obtained by passing 20 ml of human  serum over a 
60b-Sepharose column and eluting with 0.1 mM triethylamine, pH 
11.5. The eluted material was dialyzed against PBS, and appeared 
as a doublet at 55 kD in SDS gels. In some experiments, this sCD14 
was additionally purified by chromatography on Mono Q. Alter- 
natively, CD14 was isolated from the urine from a nephrotic pa- 
tient by affinity  chromatography on an MEM-18-Sepharose  column 
as previously described (16). 
Death of  Bovine Endothelial Cells in Response to LPS.  CPAE  cells 
were obtained from American Type Culture CoUection (Rockville, 
MD) (CCL 209) and maintained in MEM (Gibco Laboratories, 
Gaithersburg, MD), 20% FCS (Gibco Laboratories), nonessential 
amino acids, penicillin (100/~g/ml) and streptomycin (100/~g/ml). 
Monolayers were grown 24-48 h in microtiter plates and washed 
in serum-free media before addition ofHib LPS and serum (6.25%) 
followed by an overnight incubation.  Cytotoxic assays using the 
tetrazolium sah 3-(4,5-dimethyhhiazol-2-yl)-2,5-diphenyl tetrazo- 
lium bromide (MTT) (M2128; Sigma Chemical Co., St. Louis, MO) 
were performed as described elsewhere (11, 17). This assay detects 
living but not dead cells using a quantitative colorimetric assay 
dependent on viable mitochondrial dehydrogenase  activity of  viable 
cells. 
Expression of  ELAM-I on HUVEC.  HUVEC were isolated and 
established as monohyer cultures on fibronectin-coated  Terasaki  wells 
in human serum-containing  medium as previously described (18). 
Some experiments  used HUVEC obtained from a commercial  source 
(Cloneties, San Diego,  CA)  and passaged four times in bovine 
serum-containing medium according to the manufacturer's instruc- 
tions. To initiate the experiment, monolayers were washed exten- 
sively in MEM containing  10/zg/ml c~2-macroglobulin (Calbio- 
chem-Behring Corp., San Diego, CA), then incubated for 4 h at 
37~  in medium supplemented with serum and Re595 LPS (List 
Biological, Campbell, CA).  The monolayers were then washed, 
and expression of ELAM-1 on the cell surface was measured as 
follows. 5/zg/ml of anti-ELAM-1 antibody BBll (19) was added 
for 30 rain. After extensive  washing, alkaline  phosphate -conjugated 
anti-routine IgG was added for an additional 30 min. After a final 
wash, cell-associated alkaline phosphatase was measured using a 
fluorogenic substrate as described above for the sCD14 ELISA. 
Results are reported in arbitrary fluorescence units averaged from 
triplicate data points. Background fluorescence  obtained in the ab- 
sence of anti-ELAM-1 antibody was subtracted from these values. 
IL6 Section by U373  Cells.  The human astrocytoma cell line 
U373 (HTB 17; American Type Culture Collection) was obtained 
from Dr. Guillemont (Santi, France) and maintained in RPMI 1640 
supplemented with 10% FCS (Gibco Laboratories). Monolayers 
of U373 cells in 24-well culture plates (Costar, Cambridge, MA) 
were washed three times in HBSS (Gibco Laboratories) before ad- 
dition of  different concentrations of  LPS from Esckerichia coli (Sigma 
Chemical Co.) with 10 ng/ml of urinary sCD14 or 100 ng/ml LBP. 
In some experiments U373 cells received 10/~g/ml of 3C10, My4, 
or CD18 antibodies and LPS. The incubations were carried out 
in AIM serum-free medium (Gibco Laboratories)  or in RPMI 1640 
(Gibco  Laboratories) supplemented  with  10%  heat-inactivated 
human  A +  serum  (The Blood  Bank,  University  Hospital  of 
Trondheim, Trondheim, Norway) as indicated in the figure legends. 
After 24 h of incubation the supernatants were harvested and as- 
sayed for IL-6  activity by using the Ib6-dependent mouse hybridoma 
cell line B.13.29 done 9 as previously described (10, 20). 
Results 
We have previously shown that LPS has  a marked cyto- 
toxic effect on CPAE endothelial cells (11). This response of 
endothelial cells to LPS requires serum (11), and occurs at 
doses of LPS as low as 1 ng/ml (Fig.  1). Concentrations of 
LPS >500 ng/mt did not decrease the cell viability further. 
Maximum toxicity varied in experiments from 20 to 70%, 
but complete cell killing was never observed, regardless of 
the LPS or serum concentrations used. 
Anti-CD14 Fails to Block Cytotoxicity if Serum from Nonpri- 
mates Is Used.  The requirement for serum and low levels 
of LPS led us to examine whether CD14 played a role in LPS- 
induced cell death.  Initial studies using bovine endothelial 
cells cultured in human serum showed a striking blockade 
ofcytotoxicity  using the anti-human CD14 mAb 3C10 (11). 
Similar results were found using a second anti-human CD14 
mAb (60b), which blocks the function of human CD14. A 
third anti-CD14 mAb (26ic), which binds CD14 but does 
not block interaction of CD14 with LPS/LBP complexes, 
did not block cytotoxicity in human serum at concentrations 
as high as 20/~g/ml (data not shown). These results suggest 
that CD14 serves in recognition of LPS by endothdial cells 
as it does in mononudear cells. Further experiments, how- 
ever, showed that 3C10 did not bind to bovine endothelial 
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Figure 1.  LPS-induced cytotoxicity for bovine endothelial cells. LPS was 
added to CPAE cells in 6.25%  human serum and incubated  overnight. 
Viability of the endothelial  cells was measured by the MTT colorimetric 
assay (17). Values are the average of four samples  •  SD. 
Table  1.  Depletion  of sCD14 frora Serum  Prevents Response 
to LPS 
Percent  cell 
Components  added  death* 
Normal  serum 
Normal serum,  LPS 
CD14-depleted  serum 
CD14-depleted  serum,  LPS 
CD14-depleted  serum,  sCD14,  LPS, 
CD14-depleted  serum,  sCD14,  3C10,  LPS 
0_+2.3 
25.6  _+  10.2 
0+1.1 
0_+5.1 
23.0  _+  6.5 
6.0  -+  4.5 
*  6.25% serum (normal or depleted) was added to CPAE endothelial cells, 
followed by addition  of immunopurified  sCD14 (4/~g/ml from human 
serum), anti-CD14 3C10 antibody (2/zg/ml), and Hib LPS (100 ng/ml) 
as indicated.  Cells were incubated  overnight before measuring  viability. 
Values are the average of four samples  _+  SD. 
cells, and pretreatment of CPAE cells with 3C10 did not affect 
their sensitivity to LPS added in a subsequent incubation (data 
not shown).  These observations suggested that the CD14 
inhibited by anti-CD14  mAb was not expressed at the sur- 
face of the endothelial cells. 
The specificity of the blocking action of 3C10 was further 
investigated in studies using bovine endothelial cells cultured 
in sera from different species. LPS-dependent cytotoxicity was 
observed  in  sera from  several different  species, including 
human, macaque monkey, fetal bovine, bovine,  horse, and 
rabbit (Fig. 2; and our unpublished results), indicating that 
all these sera contain the activities necessary for mediating 
a response to LPS. However, the anti-CD14  antibody 3C10 
(2/zg/ml) prevented cytotoxicity  only with sera from human 
and macaque sources, not from other species (Fig. 2). Similar 
results were obtained with a second anti-human CD14 mAb, 
60b (data not shown). An ELISA using 3C10 showed a strong 
signal from both human and macaque serum, but no signal 
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Figure 2.  LPS-directed cytotoxicity with sera from various sources and 
blockage with anti-human CD14 antibody.  LPS (100 rig/m1) was added 
to CPAE cells (where indicated) with sera from different animal sources 
(6.25%) and incubated  overnight followed by measurement  of cell via- 
bility. 3C10, a CD14 blocking mAb, was added at 2/*g/ml where indi- 
cated before addition of LPS. Values are the average of four samples +_ SD. 
from sera from the other species (data not shown). These 
results suggest that molecules in the serum rather than on 
the cell surface represent the targets recognized by anti-CD14 
mAbs. 
Depletion of sCD14 from Plasma Blocks Its Ability to Support 
LPS-mediated Cytotoxicity.  CD14 is found not only on the 
surface of phagocytes but also in the plasma (16, 21). Bazil 
and Strominger (22) have shown that CD14 may be released 
from the surface of monocytes and appears in the plasma of 
healthy adults at concentrations  "~5 t~g/ml. To determine if 
the sCD14 in plasma participates in responses of endothelial 
cells to LPS, human serum was depleted of CD14 by affinity 
chromatography  on anti-CD14-Sepharose. Serum depleted of 
CD14 in this way failed to support  a cytotoxic response of 
CPAE to LPS (Table 1). 
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Figure 3.  Expression of ELAM-1 on HUVEC in response to LPS and 
serum.  Monohyers of HUVEC cultured in bovine serum were washed 
and incubated for 15 min at 37~  in the presence (open squares) or absence 
of 50/zg/ml 3C10. Monolayers were washed thoroughly, then incubated 
for 4 h with the indicated concentrations of LPS (Re) in the presence (filled 
circles) or absence (open circles) of 0.5% NHS. 3C10 (50/*g/ml) was added 
to the NHS in one set (open triangles). ELAM-1 expression was measured 
as described in Materials  and Methods. 
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depleted plasma to support a response to LPS was caused by 
depletion of CD14, not other factors. LPS-binding proteins 
in plasma such as LBP or septin were not depleted by the 
anti-CD14 column since the depleted plasma showed unaltered 
ability to opsonize LPS-coated erythrocytes for recognition 
by macrophages (data not shown). Further, the depleted serum 
was fully capable of supporting responses of CD14-bearing 
cells to LPS: it showed unaltered ability to enable PMN to 
respond to LPS with enhanced activity of the leukocyte inte- 
grin CR3 and to enable monocytes to respond to LPS with 
secretion of TNF (data not shown). Anti-CD14 is unlikely 
to contaminate the CD14-depleted serum since both of these 
assays are blocked by anti-CD14 (1, 6). Moreover, an ELISA 
for anti-CD14 in the depleted serum failed to show contami- 
nation (see Materials and Methods).  Finally, the ability of 
depleted serum to support  a response of endothelial cells to 
LPS was restored by readdition  of sCD14 to the depleted 
plasma (Table 1). These observations thus indicate that sCD14 
is necessary for bovine endothelial cells to respond to LPS. 
sCD14 Is Needed for Induction of  ELAM-I on HUVEC.  LPS 
has been shown to induce the expression of the adhesion pro- 
tein ELAM-1 (E-selectin) on HUVEC in serum-containing 
medium (8). We found that serum is absolutely required for 
the response of these cells to LPS (Fig. 3), indicating a re- 
quirement for soluble proteins. As with bovine endothelial 
cells, the induction of ELAM-1 by LPS required CD14 since 
the response was completely  blocked with anti-CD14 mAbs 
3C10 (Fig. 3) or 60b (Fig. 4), but was unaffected by a control 
mAb directed against CD18 (IB4; data not shown), mCD14 
does not appear to play an essential role in the response of 
HUVEC to LPS since a pretreatment of HUVEC monolayers 
with anti-CD14 antibody 3C10 caused no change in the ability 
of the monolayers to respond to LPS and serum (Fig. 3). On 
the other hand, depletion of sCD14 from the serum com- 
pletely abolished its ability to support synthesis of ELAM-1 
in response to LPS (Fig. 4), and this response was restored 
by the addition of sCD14 (Fig. 5). These results confirm that 
sCD14 in serum plays a crucial role in the response of HUVEC 
cells to LPS. 
sCD14 Is Required for Secretion of lL6 by U373 Cells in Re- 
sponse to LPS.  U373 cells are human astrocytoma cells that 
respond to LPS by secreting Ib6 in a serum-dependent fashion 
(10a and Fig.  7).  Experiments were carried  out to  study 
whether CD14 is involved in this induction of II.-6. Different 
concentrations  of LPS  in  10%  A + NHS  were added  to 
U373 cells in the absence and presence of 10/~g/ml of 3C10, 
My4, or anti-CD18.  Both the anti-CD14  mAbs 3C10 and 
My4 markedly inhibited LPS-induced  II:6 production whereas 
CD18 antibodies had no effect (Fig. 6). Since  U373 cells ex- 
press no detectable surface CD14 (10a), these results suggest 
that CD14 in serum may also be essential for the LPS re- 
sponse in U373  cells. 
To confirm a role for sCD14 in the response of U373 cell 
to LPS, IL-6 secretion was measured in the presence of  purified 
LBP and sCD14. LBP alone was incapable of enabling a re- 
sponse to LPS (10a and Fig. 7). Parallel studies confirmed 
that the LBP used in these experiments was active  in enhancing 
the responses of monocytes to LPS (data not shown).  This 
result confirms that binding of  LPS/LBP comple~es  to mCD14 
does not account for production of I1-6 in U373 cells and 
indicates that serum contains factors in addition to LBP that 
are required for cell stimulation. Addition of sCD14 and LBP, 
on the other hand, enabled strong LPS-dependent stimula- 
tion of II.-6 production (Fig. 7). Further studies showed that 
addition of sCD14 alone, in the apparent  absence of LBP, 
also enabled responses to LPS. Addition of 10 ng/ml sCD14 
in AIM serum-flee medium resulted in a >10-fold increase 
in the amount of IL-6 induced by 10 and 100 #g/ml of LPS. 
The ability of LPS to induce I1.-6 in the presence of sCD14 
was •10-fold  less than in the presence of 10% NHS. Addi- 
tion of 100 ng/ml LBP to sCD14 did not affect the LPS- 
mediated response under serum-free  conditions. The enhanced 
response to LPS by sCD14 could be blocked by 3C10 (data 
not shown). These data thus demonstrate that sCD14 is neces- 
sary for U373  cells to respond  to LPS. 
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Figure 4.  Depletion of sCD14 from NHS prevents a 
response of HUVEC to LPS. Monolayers of HUVEC were 
grown in human serum containing medium, washed, then 
incubated for 4 h with the indicated concentrations  of Re 
LPS in the presence of medium alone (circles), 0.5% NHS 
(squares), 0.5% NHS containing anti-CD14 mAb 60b (tn'- 
angles),  or with CD14-depleted NHS (diamonds).  Mono- 
layers were washed, and ~pression of ELAM-1 was mea- 
sured as described in Materials and Methods.  Results are 
representative  of six separate studies. 
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Figure 5.  Addition of sCD14 restores ability of serum to enable a re- 
sponse to LPS. Monolayers of HUVEC were grown in bovine serum-con- 
taining medium, washed, then incubated for 4 h in the presence or ab- 
sence  of LPS  (5  ng/ml),  NHS  (0.5%),  CD14-depleted  serum  (0.5%) 
reconstituted with 0.5 #g/ml of sCD14. The sCD14 used in this study 
was purified from NHS by sequential chromatography on anti-CD14 and 
Mono Q.  Results  are representative of two experiments. 
Discussion 
Previous studies have shown that mCD14  on monocytes 
and PMN is necessary for the responses of these cells to LPS 
(1, 6). Here we show that CD14 is also necessary for CPAE, 
HUVEC, and U373 cells to respond to LPS. In contrast with 
the phagocytic leukocytes studied previously, CPAE, HLrVEC, 
and U373 cells do not express mCD14 at their cell surfaces. 
The CD14 required by these cells derives, instead, from sCD14 
present in serum. These results suggest  that sCD14 in the 
plasma may play a significant role in responses of animals 
to LPS, and that CD14 may play a role in the responses of 
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Figure 6.  Inhibition of LPS-induced II.-6 production in U373 cells by 
CD14 antibodies. Different concentrations of LPS in 10% N HS ([]) with 
10/~g/ml of 3C10 (&,), My4 ('),  or CD18 antibodies (m) were added 
to U373 cells. Supernatants were harvested after 24 h and assayed for IL-6 
levels. Addition of antibodies to U373 ceils without LPS did not inhibit 
the spontaneous release of Ib6 from the cells. 
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Figure 7.  sCD14 is required for induction of IL-6 in U373 by LPS. 
Different concentrations of LPS were added to U373 cells in AIM serum- 
free medium (O) with 100 ng/ml LBP (V),  10 ng/ml sCD14 (I),  or 
100 ng/ml LBP +  10 ng/ml sCD14 (A). The LPS response in 10% NHS 
in RPMI 1640 (O) was included for comparison. Supernatants were har- 
vested after 24 h and assayed for IL-6 levels. 
many additional cell types, including  those that do not ex- 
press mCD14. 
sCD14 is abundant in plasma, accounting for at least 99% 
of the total CD14 content  of blood. Maliszewski  (23)  has 
suggested that the sCD14 could act to bind and neutralize 
LPS/LBP complexes, thus inhibiting responses to endotoxin. 
Our results suggest the opposite. The sCD14 enables responses 
of cells that do not express mCD14,  and sCD14 certainly 
does not block the response of monocytes,  which respond 
briskly to LPS in whole blood. 
sCD14 is elaborated into the medium by mononuclear cells 
in vitro (16, 22). These studies have suggested that cell sur- 
face CD14 is released into the medium through a proteolytic 
mechanism,  but  direct secretion  of  sCD14,  without  a 
membrane-bound intermediate, has not been ruled out. Since 
sCD14 is thought to lack a GPI anchor (16),  these results 
suggest  that the GPI anchor is not necessary for CD14 to 
perform its role in signal transduction. 
How does sCD14,  without a GPI anchor, participate in 
signal transduction? Since sCD14 must interact with cells 
in some way to stimulate them, we suggest that sCD14 must 
interact with some additional component on the membrane 
to bring  about association with the cell and signaling of a 
response. We thus propose that sCD14 binds to an additional 
receptor subunit on the surface of the endothelial cells and 
U373 cells. Since sCD14 is not normally associated with the 
cell surface of these cells, we propose that sCD14 only in- 
teracts with this additional subunit after ligation  of CD14 
by an LPS/LBP on an LPSAeptin complex. Precedent for such 
a mechanism  is provided by the receptor for II.-6. Recent 
studies have shown that the ligand-binding  80-kD subunit 
of the II-6 receptor interacts with a signal-transducing 130-kD 
1669  Frey et al. subunit only after binding of IL-6 (24). Moreover, both soluble 
80-kD as well as membrane-bound 80-kD proteins may bind 
I1:6,  associate  with the  130-kD  subunit,  and transduce a 
signal (24). 
Previous  studies have shown that LPS triggers responses 
in monocytes and PMN by interacting first with the serum 
proteins LBP or septin (1-3,  6).  The resulting complex of 
LPS/LBP or LPSAeptin then interacts with mCD14 and cel- 
lular responses are initiated. By analogy with results obtained 
with monocytes and PMN, we propose that LPS first interacts 
with serum-binding proteins such as LBP or septin, and the 
resulting complex then interacts with sCD14 to initiate cel- 
lular responses.  We wish to point out, however,  that a re- 
quirement for LBP or septin in the function of sCD14 has 
not been formally proven by our experiments. Indeed sCD14 
and LPS alone, without intentional addition of  LBP or septin, 
caused strong I1,6 secretion by U373 cells, and a similar re- 
sponse to LPS and sCD14 was observed in both CPAE and 
HUVEC (data not shown). It is not presently clear whether 
our preparations of sCD14 are contaminated with LBP or 
septin, or whether a novel mechanism, independent of LBP 
or septin, is involved in the stimulation of cells by LPS and 
sCD14. The details of the mechanism by which sCD14 stimu- 
lates cells are currently under investigation in our laboratories. 
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